Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adding Bv improved survival for some Hodgkin patients

Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

Publish date:: September 28, 2018

Key clinical point: Brentuximab vedotin (Bv), given before and after standard chemotherapy, improved survival in untreated Hodgkin lymphoma.

Major finding: Two-year PFS was 84% for patients treated additionally with Bv, compared with 50% historically for standard therapy.

Study details: A prospective phase 2 study involving 48 elderly patients with Hodgkin lymphoma.

Disclosures: Seattle Genetics supported the investigator-initiated trial. Dr. Evens reported consulting or advisory relationships with Seattle Genetics and several other companies.

Read the article.

Citation:

Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

This Week's Must Reads

TNBC: Adding capecitabine boosts disease-free survival in prospective trial,

Pembrolizumab plus chemo boosts pCR rate in TNBC,

Promising new neoadjuvant strategy in luminal B breast cancer,

APHINITY 6-year data: Benefit ongoing in HER2+ early BC, no significant OS benefit,

Ten-Year Results Support Partial Breast Irradiation,

Must Reads in Hodgkin Lymphoma

Worse PFS when radiation is withheld in early-stage Hodgkin lymphoma,

Cell count ratios appear to predict thromboembolism in lymphoma,

Regimen shows promise as salvage for classical HL,

Adding Bv improved survival for some Hodgkin patients, Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.

Substantial late mortality risk persists after childhood BMT , Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.